TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05915286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Study: NCT04273360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive use group
Description: Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
Study: NCT05595928

Intervention type: OTHER
Intervention: position
Description: To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.

Intervention type: OTHER
Intervention: position
Description: To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.

Intervention type: OTHER
Intervention: position
Description: To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
Study: NCT05558384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: A 15-week standardized aerobic exercise intervention.~* Frequency: 5 days/wk (2 supervised)~* Intensity: 50-59% heart rate reserve~* Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~* Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)
Study: NCT05027074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered via IV infusion
Study: NCT06108687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water spray application
Description: cold water kept in the refrigerator at +4 degrees
Study: NCT05992701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimualtion
Description: Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
Study: NCT05207813

Intervention type: DEVICE
Intervention: Intracept Procedure
Description: Intraosseous Basivertebral Nerve (BVN) Ablation
Study: NCT04252235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air purifier
Description: The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham air purifier
Description: The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
Study: NCT06482567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCOVER
Description: The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Presence with Reassurance
Description: The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
Study: NCT06040541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral Tablets
Study: NCT06290388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23ME-01473
Description: 23Me-01473 given by intravenous infusion
Study: NCT06225466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.

Intervention type: OTHER
Group type: OTHER
Intervention: Anesthesia without neuromuscular blockade
Description: Anesthesia without rocuronium or sugammadex
Study: NCT05672966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL, Intramuscular
Study: NCT05478330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide 1% gel
Description: Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical gel without flutamide
Description: Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
Study: NCT05089526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-lidocaine-dexmedetomidine
Description: In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Study: NCT05868096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured holistic thinking course(2 hr)
Description: The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical practice training
Description: there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
Study: NCT05963048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL6 inhibitor
Description: 6 mg/kg I V infusion monthly
Study: NCT04079660

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary blood glucose blood draw
Description: Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
Study: NCT05556902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent Epidural Spinal Cord Stimulation
Description: Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
Study: NCT05578014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
Study: NCT04998786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
Study: NCT06218303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide Vaccine
Description: MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol®
Description: A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
Study: NCT05578014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
Study: NCT06309316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC)
Description: In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
Study: NCT04785157

Intervention type: BIOLOGICAL
Intervention: serology testing profiles description
Description: SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)

Intervention type: BIOLOGICAL
Intervention: immune response characterization
Description: systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)

Intervention type: OTHER
Intervention: in vivo brain PET-TSPO acquisitions
Description: in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)

Intervention type: OTHER
Intervention: brain MRI assessment
Description: structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)

Intervention type: BEHAVIORAL
Intervention: neurocognitive assessment
Description: multi-domains neurocognitive assessment
Study: NCT05503251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Assessment
Description: Undergo neuropsychological evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04784884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSI
Description: diagnostic hyperspectral imaging
Study: NCT05510024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy
Description: The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCIT
Description: Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
Study: NCT06407024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic transabdominal adrenalectomy
Description: Adrenalectomy performed by laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic transabdominal adrenalectomy
Description: Adrenalectomy performed by robotic approach
Study: NCT05028959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary monitoring of healthy women
Description: Multidisciplinary monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary monitoring of healthy women
Description: Multidisciplinary monitoring
Study: NCT04783012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter removal
Description: Catheter management strategy after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter removal
Description: Catheter management strategy after surgery
Study: NCT05173779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial isolation by catheter ablation
Description: Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
Study: NCT06652295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive physiotherapy (CDP)
Description: CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered Complex Decongestive Physiotherapy (CDP)
Description: The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
Study: NCT05411497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MUC1-activated T-cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT06650384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin
Description: Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
Study: NCT04357951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
Study: NCT05473000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Submaximal and maximal exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Submaximal and maximal exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Delivery of ozone air pollution at 170ppb
Study: NCT06650384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
Description: Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
Study: NCT06586398

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Participants will be randomized to 15 sessions of double-blind multi-target rTMS treatment (active vs sham) and then will receive only open-label active stimulation for another 15 sessions. Each session will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Participants will be randomized to 15 sessions of double-blind multi-target rTMS treatment (active vs sham) and then will receive only open-label active stimulation for another 15 sessions. Each session will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).
Study: NCT06662279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Rapid Palatal Expander
Description: Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded Palatal Expander
Description: Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
Study: NCT06658366

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: impression of the teeth
Description: Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
Study: NCT06586281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
Study: NCT04357951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Description: All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
Study: NCT06525545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early mobilizzation of the ankle
Description: perform flexion-extension exercises of the operated ankle
Study: NCT04971577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin 40mg
Description: participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night